Cargando…

Protecting Patients from Adverse Drug Events: Propoxyphene, PIMs, and Drugs to Avoid in Older Adults

Detalles Bibliográficos
Autores principales:	Curtiss, Frederic R., Fairman, Kathleen A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2011
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438314/ https://www.ncbi.nlm.nih.gov/pubmed/21204591 http://dx.doi.org/10.18553/jmcp.2011.17.1.60

Ejemplares similares

Preventing Medication Errors and Adverse Drug Events
por: Curtiss, Frederic R.
Publicado: (2003)

Diabetes Drug Therapy -- First Do No Harm
por: Curtiss, Frederic R., et al.
Publicado: (2008)

Regulatory Actions on the Off-Label Use of Prescription Drugs: Ongoing Controversy and Contradiction in 2009 and 2010
por: Fairman, Kathleen A., et al.
Publicado: (2010)

The Elephant in the Pharmacy: Patient Choice Is the Big Challenge That No One Talks About in Affordability of Prescription Drugs
por: Fairman, Kathleen A., et al.
Publicado: (2007)

How Do Seniors Respond to 100% Cost-Sharing for Prescription Drugs? Quality of the Evidence Underlying Opinions About the Medicare Part D Coverage Gap
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Switching Antidepressant Drug Therapy Helps Some Patients Some of the Time--What TORDIA, STAR*D, and Observational Research Have Taught Us About Treatment-Resistant Depression
por: Curtiss, Frederic R., et al.
Publicado: (2008)

It Depends on What Mean Means: Averaging Versus Event Patterning in Analyses of Administrative Claims Data
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
por: Katsuno, Hayato, et al.
Publicado: (2021)

Pharmacogenetics to Avoid Adverse Drug Reactions
por: López-Fernández, Luis A.
Publicado: (2022)

Dextro Propoxyphene and the Ventilatory Response to Carbon Dioxide in Man
por: Burget, Dean E., et al.
Publicado: (1962)

Lessons Learned from Randomized Trials and Recent Experience with Health Information Technology: Promising Interventions Meet Real-World Patient Care
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Evidence-Based Medicine: Which Drugs Are Truly Contraindicated for Use in Older Adults?
por: Curtiss, Frederic R.
Publicado: (2005)

Precision dosing to avoid adverse drug reactions
por: Polasek, Thomas M., et al.
Publicado: (2019)

Does Medicalization of Life Imperil Health? Expanding Indications for Diagnosis and Treatment of Chronic “Disease”
por: Fairman, Kathleen A., et al.
Publicado: (2011)

What Do We Really Know About VBID? Quality of the Evidence and Ethical Considerations for Health Plan Sponsors
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Still Looking for Health Outcomes in All the Wrong Places? Misinterpreted Observational Evidence, Medication Adherence Promotion, and Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Call for Letters Regarding Disclosure of Potential Conflicts of Interest in the Managed Care Literature -- Too Much, Too Little, or Just About Right?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Tough Questions About the Value of Statin Therapy for Primary Prevention: Did JUPITER Miss the Moon?
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Clinical Quality Indicators and Provider Financial Incentives: Does Money Matter?
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Managed Care and Health Care Reform: Everything Old Is New Again
por: Fairman, Kathleen A., et al.
Publicado: (2009)

VBID, the PPACA, and FREEE Medications: Did Politics Trump the Evidence About Cost Sharing?
por: Fairman, Kathleen A., et al.
Publicado: (2012)

ADD or ADHD or What Exactly?--GIGO Part II and Other Lessons in Research with Administrative Claims
por: Curtiss, Frederic R., et al.
Publicado: (2007)

Rethinking the Whodunnit Approach to Assessing the Quality of Health Care Research -- A Call to Focus on the Evidence in Evidence-Based Practice
por: Fairman, Kathleen A., et al.
Publicado: (2008)

What Should Be Done About Bias and Misconduct in Clinical Trials?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Making the World Safe for Evidence-Based Policy: Let's Slay the Biases in Research on Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Selling Real-World Health Care Research to Reluctant Buyers-Evidence-Based Education or Marketing a Defective Product?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

It's Only a Pharmacoeconomic Model--Believe It or Not
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Call for Comparative Effectiveness Research: Lowering A1c with Sitagliptin, Saxagliptin, or Cinnamon
por: Fairman, Kathleen A., et al.
Publicado: (2009)

False-Positive Versus True-Positive Drug-Drug Interactions With Warfarin
por: Curtiss, Frederic R.
Publicado: (2006)

Nonadherence, Clinical Inertia, or Therapeutic Inertia?
por: Allen, J. Daniel, et al.
Publicado: (2009)

Prior Authorization and Clopidogrel Use - The Truth Lies in the Details
por: Jackson, Mark A., et al.
Publicado: (2009)

The Future of Prescription Drug Cost-Sharing: Real Progress or Dropped Opportunity?
por: Fairman, Kathleen A.
Publicado: (2008)

Prior Authorization to Manage Drug Utilization and Costs
por: Curtiss, Frederic R.
Publicado: (2003)

Burden of Prescription Drug Costs in the United States
por: Curtiss, Frederic R.
Publicado: (2003)

Hypertension, Prescription Drug Copayments, and Drug Therapy Adherence
por: Curtiss, Frederic R.
Publicado: (2003)

COX-2 Inhibitors: Little or No GI Protection, Increased Risk of Cardiovascular Events, High Cost, and Other Class-less Effects
por: Curtiss, Frederic R.
Publicado: (2005)

HIPAA Effects on Health Research and PBM Functions in Drug Utilization Review
por: Curtiss, Frederic R.
Publicado: (2003)

Reporting adverse drug events to the Therapeutic Goods Administration
por: Martin, Jennifer H, et al.
Publicado: (2021)

Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy--Prasugrel Versus Clopidogrel
por: Curtiss, Frederic R.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_utmggn3j86587mu93g950gt9rm